Fox Run Management L.L.C. Acquires 5,436 Shares of DexCom, Inc. $DXCM

Key Points

• Fox Run Management L.L.C. boosted its stake in DexCom, Inc. by 175.5%, acquiring an additional 5,436 shares to total 8,533 shares valued at approximately $583,000.
• Insider trades included Sadie Stern and Mark G. Foletta, who sold 1,466 and 2,750 shares, respectively, indicating a small decrease in their positions.
• DexCom reported a 15.2% year-over-year revenue increase with a quarterly revenue of $1.16 billion and beat EPS estimates by $0.03.

Fox Run Management L.L.C. lifted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 175.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,533 shares of the medical device company's stock after acquiring an additional 5,436 shares during the quarter. Fox Run Management L.L.C.'s holdings in DexCom were worth $583,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in DXCM. Nuveen LLC bought a new stake in shares of DexCom in the first quarter worth $554,893,000. Jennison Associates LLC lifted its stake in shares of DexCom by 37.7% in the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after purchasing an additional 2,879,489 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of DexCom by 171.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock worth $218,175,000 after buying an additional 2,015,971 shares during the last quarter. Federated Hermes Inc. grew its position in DexCom by 2,371.4% during the first quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company's stock valued at $136,220,000 after buying an additional 1,914,019 shares during the period. Finally, Vanguard Group Inc. increased its holdings in DexCom by 2.0% during the first quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company's stock valued at $3,240,763,000 after buying an additional 925,882 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the sale, the executive vice president directly owned 109,621 shares in the company, valued at $9,329,843.31. The trade was a 5.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the transaction, the executive vice president owned 94,102 shares of the company's stock, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,906 shares of company stock valued at $1,832,451. Corporate insiders own 0.32% of the company's stock.

DexCom Price Performance

Shares of NASDAQ:DXCM traded up $1.5890 during midday trading on Friday, reaching $82.2090. 1,358,604 shares of the company were exchanged, compared to its average volume of 3,862,880. The stock has a market cap of $32.24 billion, a PE ratio of 57.12, a price-to-earnings-growth ratio of 1.71 and a beta of 1.43. The business's fifty day moving average is $82.81 and its two-hundred day moving average is $79.93. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom's revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

DXCM has been the subject of several analyst reports. William Blair upgraded DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Barclays upped their price target on DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Mizuho raised their price objective on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Argus started coverage on DexCom in a research note on Thursday. They set a "buy" rating and a $100.00 price objective for the company. Finally, The Goldman Sachs Group started coverage on shares of DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $99.90.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.